Prasad Narayan, Yadav Brijesh, Singh Mantabya, Gautam Sonam, Bhadauria Dharmendra, Patel Manas, Kushwaha Ravi, Yadav Deependra, Singh Ankita, Yachha Monika, Behera Manas, Kaul Anupama
Department of Nephrology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow, Lucknow 226014, India.
Vaccines (Basel). 2022 Mar 3;10(3):385. doi: 10.3390/vaccines10030385.
Vaccination-induced SARS-CoV-2 neutralizing antibodies are required for herd immunity. Vaccine availability and poor vaccine response in renal transplant recipients (RTRs) remain a concern. There is no report on the efficacy of Covaxin and Covishield vaccines in RTRs. We recruited 222 live donors RTRs and analyzed the serum titer of anti-SARS-CoV-2 spike protein antibody by chemiluminescent magnetic microparticle immunoassay. Patients were categorized into three groups: group1 with SARS-CoV-2 infection and no vaccination ( = 161); group 2 with only vaccination and no SARS-CoV-2 infection ( = 41); and group 3 with both vaccination and SARS-CoV-2 infection ( = 20). Overall seroconversion rate was 193/222 (86.9%) with a median titer 1095.20 AU/mL. The median IgG titer value in group 1 was 647.0 AU/mL; group 2 was 1409.0 AU/mL; and group 3 was 1831.30 AU/mL. Covaxin associated seroconversion was observed in 16/19 (84.21%), with a median titer of 1373.90 AU/mL compared to that of Covishield 32/42 (76.19%), whose median titer was 1831.10 AU/mL. The seroconversion rate due to SARS-CoV-2 infection was 145 (90.06%), it was lowest with the vaccination-only group (70.7%), and with both vaccination and SARS-CoV-2 infection group it was highest (95%). In RTRs, SARS-CoV-2 infection and both Covaxin and Covishield vaccination effectively induce a humoral immune response against the SARS-CoV-2 spike protein; however, seroconversion rate was lower and the antibody titer was higher with vaccine than infection.
群体免疫需要接种疫苗诱导产生的抗SARS-CoV-2中和抗体。肾移植受者（RTRs）中疫苗的可及性以及较差的疫苗反应仍是一个令人担忧的问题。目前尚无关于Covaxin和Covishield疫苗在RTRs中疗效的报道。我们招募了222名活体供肾的RTRs，并通过化学发光磁微粒免疫分析法分析了抗SARS-CoV-2刺突蛋白抗体的血清滴度。患者被分为三组：第1组为感染SARS-CoV-2但未接种疫苗（n = 161）；第2组为仅接种疫苗但未感染SARS-CoV-2（n = 41）；第3组为既接种疫苗又感染SARS-CoV-2（n = 20）。总体血清转化率为193/222（86.9%），中位滴度为1095.20 AU/mL。第1组的IgG中位滴度值为647.0 AU/mL；第2组为1409.0 AU/mL；第3组为1831.30 AU/mL。观察到Covaxin相关的血清转化率为16/19（84.21%），中位滴度为1373.90 AU/mL，而Covishield为32/42（76.19%），中位滴度为1831.10 AU/mL。由SARS-CoV-2感染导致的血清转化率为145（90.06%），仅接种疫苗组最低（70.7%），既接种疫苗又感染SARS-CoV-2组最高（95%）。在RTRs中，SARS-CoV-2感染以及Covaxin和Covishield疫苗接种均能有效诱导针对SARS-CoV-2刺突蛋白的体液免疫反应；然而，疫苗接种后的血清转化率较低，抗体滴度高于感染后的情况。
